NEW YORK (GenomeWeb) – Medicare contractor Noridian has issued a final local coverage decision (LCD) for Myriad Genetics' Prolaris, a test for gauging prostate cancer aggressiveness.

In January this year, another Medicare contractor, Palmetto GBA, issued a final LCD on the same test when used for low- and very low-risk prostate cancer patients. Similarly, the final LCD from Noridian, which goes into effect on October 15, will cover testing for prostate cancer patients defined as low and very low risk by the National Comprehensive Cancer Network. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.